Research advances in the association of drug-induced liver injury with polymorphisms in human leukocyte antigen

被引:4
|
作者
Ma, Qingmei [1 ]
Yang, Wenjuan [1 ]
Wang, Lu [1 ]
Ma, Li [1 ]
Jing, Yanmei [1 ]
Wang, Jiamei [1 ]
Liu, Xinyue [1 ,2 ]
机构
[1] Lanzhou Univ, Dept Pharmacogen Lab Ctr, Hosp 2, Lanzhou 730030, Gansu, Peoples R China
[2] Lanzhou Univ, Dept Clin Lab Ctr, Hosp 2, Lanzhou 730030, Gansu, Peoples R China
关键词
Hepatotoxicity; Adverse drug reactions; Genetic polymorphism; Biomarkers; Pharmacogenomics; CLINICAL CHARACTERISTICS; HLA; HEPATOTOXICITY; SUSCEPTIBILITY; GENOTYPE; FEATURES; RISK; FLUCLOXACILLIN; CARBAMAZEPINE; DIAGNOSIS;
D O I
10.1016/j.intimp.2019.106037
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Drug-induced liver injury is an important adverse drug reaction. Due to the lack of specificity in clinical symptoms and pathological features, there are still no reliable diagnostic biomarkers, so drug-induced liver injury is a diagnosis of exclusion. The article reviews the relevant advances in the association between novel human leukocyte antigen gene polymorphisms and drug-induced liver injury in order to identify potential biomarkers and provide a new method for the prediction and diagnosis of drug-induced liver injury. Henceforth, while studying the association between them, it will also need that the large sample and prospective studies to gain supporting evidence to implement translational application, so as to improve the safety and effectiveness of medication and achieve individualized treatment.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Drug-induced liver injury: past, present and future
    Daly, Ann K.
    PHARMACOGENOMICS, 2010, 11 (05) : 607 - 611
  • [32] Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST
    Santos, Eliana Abreu
    Saraiva Goncalves, Jose Carlos
    Fleury, Marcos K.
    Kritski, Afranio L.
    Oliveira, Martha M.
    Velasque, Luciane S.
    Lapa e Silva, Jose Roberto
    Estrela, Rita de Cassia E.
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2019, 23 (06) : 381 - 387
  • [33] Drug-induced liver injury
    Bjornsson, Einar S.
    LAEKNABLADID, 2010, 96 (03): : 175 - 182
  • [34] Predictive Genetic Testing for Drug-Induced Liver Injury: Considerations of Clinical Utility
    Alfirevic, A.
    Pirmohamed, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (03) : 376 - 380
  • [35] Drug-Induced Liver Injury
    McAtee, Cathy
    CRITICAL CARE NURSING CLINICS OF NORTH AMERICA, 2022, 34 (03) : 267 - 275
  • [36] Recent advances in the diagnosis of drug-induced liver injury
    Ahmed, Taqwa
    Ahmad, Jawad
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (02) : 186 - 192
  • [37] Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis: the influence of human leucocyte antigen alleles
    Stephens, Camilla
    Castiella, Agustin
    Gomez-Moreno, Eva M.
    Otazua, Pedro
    Lopez-Nevot, Miguel-Angel
    Zapata, Eva
    Ortega-Alonso, Aida
    Ruiz-Cabello, Francisco
    Medina-Caliz, Inmaculada
    Robles-Diaz, Mercedes
    Soriano, German
    Roman, Eva
    Hallal, Hacibe
    Moreno-Planas, Jose M.
    Prieto, Martin
    Andrade, Raul J.
    Isabel Lucena, M.
    PHARMACOGENETICS AND GENOMICS, 2016, 26 (09) : 414 - 422
  • [38] Drug-Induced Liver Injury
    Leise, Michael D.
    Poterucha, John J.
    Talwalkar, Jayant A.
    MAYO CLINIC PROCEEDINGS, 2014, 89 (01) : 95 - 106
  • [39] Drug-induced liver injury: a safety review
    Garcia-Cortes, Miren
    Ortega-Alonso, Aida
    Lucena, M. Isabel
    Andrade, Raul J.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (08) : 795 - 804
  • [40] The Natural History of Drug-Induced Liver Injury
    Bjornsson, Einar
    SEMINARS IN LIVER DISEASE, 2009, 29 (04) : 357 - 363